Brief: Medexus Pharmaceuticals Says Treosulfan NDA Resubmitted To FDA

Medexus Pharmaceuticals

25/07/2022 12:27

July 25 (Reuters) - Medexus Pharmaceuticals Inc  MDP.TO :
    * TREOSULFAN NDA RESUBMITTED TO FDA
    * MEDEXUS PHARMACEUTICALS INC - FDA DECISION EXPECTED WITHIN
SIX
MONTHS OF ACCEPTANCE
    * MEDEXUS PHARMACEUTICALS - PIVOTAL PHASE 3 CLINICAL TRIAL
OF
TREOSULFAN MET PRIMARY ENDPOINT AND KEY SECONDARY ENDPOINTS

Source text for Eikon:  ID:nGNX71kF3W 
Further company coverage:  MDP.TO 

 ((Reuters.Briefs@thomsonreuters.com;))